Stefania Guerra Director Scientific Affairs at Dexcom talks to Professor Helen R. Murphy about her landmark study; AiDAPT which looks at the use of hybrid closed loop in pregnancy amongst pregnant women with type 1 diabetes.

Helen will give the background to this randomised controlled trial undertaken during the pandemic and the results showing how automated insulin delivery (AID) in pregnancy can support the tight time in range that is so important for people living with diabetes who are pregnant. They will also explore why this is so important across all stages of pregnancy and the future implications on the care of pregnant women of this study and its results. A great listen for anyone looking after people who are pregnant with type 1 diabetes. Refs for description.

With; Stefania Guerra Ph.D, Msc. Director Scientific Affairs, Dexcom & Professor Helen R. Murphy MBBChBAO, MD, FRACP

Clinical Papers mentioned;
Tara T M Lee, et al. AiDAPT: automated insulin delivery amongst pregnant women with type 1 diabetes: a multicentre randomized controlled trial - study protocol. BMC Pregnancy Childbirth. 2022 Apr 5;22(1):282.
Feig, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet, 2017 Nov 25;390(10110):2347-2359.


Lawton J, et al. Listening to women: experiences of using closed-loop in type 1 diabetes pregnancy. Diabetes Technol Ther, 2023 Dec;25(12):845-855.

MAT-5077

This podcast has been created and fully funded by Dexcom UK & Ireland and intended for healthcare professionals practising in the United Kingdom & Ireland.

Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice.

All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom User Guide . For product-related questions, please refer to the instructions for use. For complete safety information, go to https://www.dexcom.com/en-gb/safety-information . Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom ONE+, Dexcom Share, Share are trademark or registered trademarks in the U.S. and may be in other countries. © 2024 Dexcom, Inc. All rights reserved. Dexcom International, Ltd. and its affiliated European entities. 1 Tanfield, Suite 6, Level 1 Tanfield, Edinburgh EH3 5DA.

Further CPD accredited education can be found on the Dexcom Education Hub